Evolution AB (publ) (EVO)
Nasdaq Stockholm · Sweden · prices in SEK · close of 27 Oct 2026
Key indicators
| Last close | SEK 828.40 |
|---|---|
| 52-week range | 515.40 – 911.00 |
| Return, 1 month / 3 months | +1.5% / +11.7% |
| Return, 1 year / 3 years | +23.1% / −8.8% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 56 |
| Volatility (1 year) | 26.8% |
| Worst drawdown (1 year) | -23.4% |
| Average daily value traded | 477.01M SEK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Evolution AB develops and supplies live casino games for online gambling operators. Its studios stream real dealers playing roulette, blackjack, baccarat and other table games to customers of licensed gaming sites, and it also provides related software and services. The company works with online casino operators in regulated markets and is based in Stockholm, Sweden.
The shares are listed on the Nasdaq Stockholm in Sweden under the code EVO, and the price on this page is in Swedish kronor (SEK). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Evolution AB (publ) (EVO) trades on the Nasdaq Stockholm in Sweden. It last closed at SEK 828.40 on 27 October 2026.
Its price-based Market X-Ray is 88 out of 100 (a strong price profile), ranking 5 of 912 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 23.1% and over the last three months it rose 11.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Nasdaq Stockholm
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 90 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 20.5% | ||
| From 52-week high | -8.0% | ||
| Momentum | 84 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 11.7% | ||
| 6-month return | 30.3% | ||
| 12-month return, skipping the last month | 21.2% | ||
| Stability (higher is calmer) | 83 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 26.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -23.4% | ||
| Liquidity | 99 · Strong | Trades actively. | |
| Average daily value traded | 477.01M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 4 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +3.5% |
|---|---|
| 1 month | +1.5% |
| 3 months | +11.7% |
| 6 months | +30.3% |
| 1 year | +23.1% |
| 3 years | −8.8% |
| 5 years | −40.4% |
Signals
| 50-day / 200-day average | 829.90 / 687.57 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 19.59 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 12 May 2025 | SEK 30.6400 |
| 29 Apr 2024 | SEK 31.0200 |
| 5 Apr 2023 | SEK 22.5400 |
| 11 Apr 2022 | SEK 14.5800 |
| 19 Apr 2021 | SEK 6.8800 |
| 18 Jun 2020 | SEK 4.4100 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Nasdaq Stockholm; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.